Blog

Transcell Oncologics (www.transcellonco.science), and it’s affiliate Transtox Bio (www.transtoxbio.com) with cell based products announced today that they have entered an academic-strategic partnership with IIT-BHU to validate natural products/cosmetics Cellular/Genotoxicity profiles building a database/signatures on stem cell based platforms. Under the terms of this agreement, School of Biomedical Engineering (Led by Dr Marshal Dayal, Associate Professor), IIT (BHU) utilizing their academic facilities and infrastructure in consultation with Transcell team agrees to complete phase 1 of generating toxicity signatures of known chemicals on Oncologics developed cell based platforms. Transcell Oncologics has developed these unique human biological discards sourced primary progenitor based platform technology being offered as products for invitro tools with predictive powers. This prediction refers to safety profiles of cosmetic products or products-in-pipeline here in this application. Transcell addresses cosmetic exploratory and regulatory testings market through it’s cell based products vertical spun out of original research and development of the applications-assays.
There are well established Toxicity testing labs, Contract Research Organizations with matured verticals offering invitro exploratory and regulatory assays for international third party companies, Ayurvedic and Herbal cosmeceuticals companies with original R&D in India who could access procure these cell based platforms from Transcell Oncologics to utilize as testing platforms in their both research and for regulatory submissions.
The stakeholders in India believe that India needs it’s own regulatory framework to test pharmaceutical formulations to release in Indian markets. When it comes to regulatory tests, Europe legislation and regulation on cosmetic products is original and has moved away from the use of animals in testing safety for human application.

www.opednews.com:

Any chemical candidate’s (natural product or synthesized) safety assessment has traditionally been based on animal testing but the European Union has been championing for many years the replacement, reduction, and refinement of animal testing protocols. Further, it is also agreed that outmoded risk assessment approaches are insufficient to adequately predict the potential risks associated with any given substance, especially when considering normal life low-dose exposure or application like that of cosmetics.
Therefore new, modern and human-based prediction models are needed to be practised both at exploratory and regulatory stages of research and development. While www.transtoxbio.com products fit into this category when it comes to applications in safety assessments.

About www.transtoxbio.com products::
All primary stem cell-based invitro real-time platforms that can predict biocompatibility, target, functional efficacy, and safety profiles of simple to complex molecules that are being investigated or developed as drug candidates. This real-time platform technology has the potential to support next-generation phenotype-based drug discovery (PDD), which is believed to be forward pharmacology. The applications spread from high throughput screening to pre-clinical till the stage of lead identification.
Its the adoption in high throughput screening extrapolates the use in drug re-positioning. The same platform can be transformed into a variety of human organ-specific cell types (like epithelium of skin/eye, osteocytes, endothelium, beating Cardiocytes, Hepatocytes) – a property that can be extrapolated in various efficacy/target related studies on investigational drug candidates. Owing to it is human-sourced stem cell composition, primary with proliferating capacities (to a passage and mimic ageing), the platform has the power to read human safety related toxicology specific, measurable endpoints after exposing to test compounds. It is the predictive property that answers critical concerns like Embryotoxicity, skin irritation, Genotoxicity, Metabolomics, and Chronic/Acute toxicity of drug able candidates.
Any platform is of great use if it is available in large quantities, which is possible only if the source is available in abundance. Transtox platforms fall under this category where the source is not donors’ biopsies that has limitations with harvest, yield, and reproducibility.
About Dr Marshal’s Research Group (Cellular Therapeutics and Biophysics laboratory) at School of Biomedical Engineering, Indian Institute of Technology (BHU), Varanasi:https://www.iitbhu.ac.in/dept/bme/people/marshalbme